FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549403992> ?p ?o ?g. }

• W2549403992 abstract "Abstract Despite improvement in the proportion of patients achieving durable remission with dose intensive consolidation strategies, leukemic relapse still occurs in 40–70% of patients who achieve an initial remission. Studies utilizing ASCT for AML in CR1 have reported relapse free survival between 34–80% based on cytogenetic risk stratification. We report a 15 year experience of ASCT following high dose cytarabine (Ara-C) ± idarubicin (IDA) consolidation in 168 patients (intent to transplant, ITT) in CR1 treated between 3/89 and 6/03. The treatment consisted of a): consolidation with high dose Ara-C ± IDA followed by marrow (M) harvest (n=64) or collection of G-CSF primed stem cells (PSCs) (n=73), b) ASCT using FTBI 12Gy, Etoposide 60mg/kg, Cytoxan 75mg/kg (n=97) or Busulfan targeted to 1st dose AUC 700–900, FTBI 1200Gy and Etoposide 30mg/kg (n=40), and c) IL-2 9x106 IU/m2/24 hrs days 1–4 and IL-2 1.6 x 106 IU/m2/24 hrs days 9–18 beginning at hematologic recovery post ASCT (from 1995-present). Patient characteristics at ITT were median age 40.8 yr. (16.3–60.9); cytogenetics (SWOG criteria) favorable = 42(25%) (including 11 M3 pre 1993), intermediate=70(42%), unfavorable=16(10%), indeterminate and unknown=40(23%); WBC <50,000=125(74%), ≥50,000=41(25%), unknown=2(1%); 147 (88%) received one induction cycle and 12% received two cycles; Ara-C induction dose was 100–200mg/m2 in 49% and 51% received high dose Ara-C induction. Median time from CR1 to consolidation was 27.6 days. Of the 168 patients consolidated, 137 had ASCT. The 100-day non-relapse mortality (NRM) for consolidation+ASCT was 2%. With a median follow up of 9.5 yrs, the 5 yr OS, DFS relapse rate (RR) for 168 ITT patients is 57%, 51%, and 41% respectively. The 5 yr OS, DFS and RR for each cytogenetic category are: favorable 64%, 63%, 29%; intermediate 58%, 50%, 41%; unfavorable 45%, 31%, 67%; and unknown cytogenetics 49%, 48%, 44% respectively. The 5 yr OS, DFS and RR for the 137 transplanted patients were 62%, 59%, and 36%. The 5 year OS and RR for favorable cytogenetics are 69%, 24%; intermediate 62%, 36%; unfavorable 55%, 58%; and unknown 55%, 42% respectively. Prognostic variables analyzed for each outcome in the ITT group were: age, WBC, cytogenetics, Ara-C induction dose, one vs. two inductions and IDA in consolidation. By multivariate analyses the number of inductions was predictive for OS with hazard ratio=2.2 (95%CI:1.2–4.3) p=0.02. No variables were found to be predictive of DFS or relapse. The same variables with the addition of conditioning regimen, IL-2 and M vs. PSCs were analyzed for the 137 transplant patients. By multivariate analysis IL-2 was predictive for OS and DFS and cytogenetics was predictive of relapse. These results demonstrate that the strategy of high dose Ara-C consolidation followed by ASCT can be performed with low NRM. This approach appears to improve the outcome of patients with all cytogenetic risk groups when compared with multiple cycles of high dose Ara-C. The role of post-transplant IL-2 appears to be beneficial and merits further investigation." @default.
• W2549403992 created "2016-11-30" @default.
• W2549403992 creator A5002340593 @default.
• W2549403992 creator A5005209077 @default.
• W2549403992 creator A5011178245 @default.
• W2549403992 creator A5015972091 @default.
• W2549403992 creator A5019268804 @default.
• W2549403992 creator A5020684790 @default.
• W2549403992 creator A5022620415 @default.
• W2549403992 creator A5024492683 @default.
• W2549403992 creator A5043320174 @default.
• W2549403992 creator A5046784402 @default.
• W2549403992 creator A5049814181 @default.
• W2549403992 creator A5052032114 @default.
• W2549403992 creator A5057798024 @default.
• W2549403992 creator A5062705128 @default.
• W2549403992 creator A5065361845 @default.
• W2549403992 creator A5070834533 @default.
• W2549403992 creator A5074606840 @default.
• W2549403992 creator A5074672999 @default.
• W2549403992 creator A5091818686 @default.
• W2549403992 date "2004-11-16" @default.
• W2549403992 modified "2023-10-01" @default.
• W2549403992 title "Analysis of Long Term Outcome in Autologous Stem Cell Transplant (ASCT) for Acute Myelogenous Leukemia (AML) in First Remission (CR1) - a 15 Year Experience." @default.
• W2549403992 doi "https://doi.org/10.1182/blood.v104.11.1870.1870" @default.
• W2549403992 hasPublicationYear "2004" @default.
• W2549403992 type Work @default.
• W2549403992 sameAs 2549403992 @default.
• W2549403992 citedByCount "0" @default.
• W2549403992 crossrefType "journal-article" @default.
• W2549403992 hasAuthorship W2549403992A5002340593 @default.
• W2549403992 hasAuthorship W2549403992A5005209077 @default.
• W2549403992 hasAuthorship W2549403992A5011178245 @default.
• W2549403992 hasAuthorship W2549403992A5015972091 @default.
• W2549403992 hasAuthorship W2549403992A5019268804 @default.
• W2549403992 hasAuthorship W2549403992A5020684790 @default.
• W2549403992 hasAuthorship W2549403992A5022620415 @default.
• W2549403992 hasAuthorship W2549403992A5024492683 @default.
• W2549403992 hasAuthorship W2549403992A5043320174 @default.
• W2549403992 hasAuthorship W2549403992A5046784402 @default.
• W2549403992 hasAuthorship W2549403992A5049814181 @default.
• W2549403992 hasAuthorship W2549403992A5052032114 @default.
• W2549403992 hasAuthorship W2549403992A5057798024 @default.
• W2549403992 hasAuthorship W2549403992A5062705128 @default.
• W2549403992 hasAuthorship W2549403992A5065361845 @default.
• W2549403992 hasAuthorship W2549403992A5070834533 @default.
• W2549403992 hasAuthorship W2549403992A5074606840 @default.
• W2549403992 hasAuthorship W2549403992A5074672999 @default.
• W2549403992 hasAuthorship W2549403992A5091818686 @default.
• W2549403992 hasConcept C126322002 @default.
• W2549403992 hasConcept C141071460 @default.
• W2549403992 hasConcept C143998085 @default.
• W2549403992 hasConcept C2776694085 @default.
• W2549403992 hasConcept C2777408962 @default.
• W2549403992 hasConcept C2778041864 @default.
• W2549403992 hasConcept C2778119113 @default.
• W2549403992 hasConcept C2778461978 @default.
• W2549403992 hasConcept C2779050716 @default.
• W2549403992 hasConcept C2779117419 @default.
• W2549403992 hasConcept C2780611847 @default.
• W2549403992 hasConcept C2911091166 @default.
• W2549403992 hasConcept C71924100 @default.
• W2549403992 hasConcept C90924648 @default.
• W2549403992 hasConceptScore W2549403992C126322002 @default.
• W2549403992 hasConceptScore W2549403992C141071460 @default.
• W2549403992 hasConceptScore W2549403992C143998085 @default.
• W2549403992 hasConceptScore W2549403992C2776694085 @default.
• W2549403992 hasConceptScore W2549403992C2777408962 @default.
• W2549403992 hasConceptScore W2549403992C2778041864 @default.
• W2549403992 hasConceptScore W2549403992C2778119113 @default.
• W2549403992 hasConceptScore W2549403992C2778461978 @default.
• W2549403992 hasConceptScore W2549403992C2779050716 @default.
• W2549403992 hasConceptScore W2549403992C2779117419 @default.
• W2549403992 hasConceptScore W2549403992C2780611847 @default.
• W2549403992 hasConceptScore W2549403992C2911091166 @default.
• W2549403992 hasConceptScore W2549403992C71924100 @default.
• W2549403992 hasConceptScore W2549403992C90924648 @default.
• W2549403992 hasLocation W25494039921 @default.
• W2549403992 hasOpenAccess W2549403992 @default.
• W2549403992 hasPrimaryLocation W25494039921 @default.
• W2549403992 hasRelatedWork W2007442696 @default.
• W2549403992 hasRelatedWork W2023291141 @default.
• W2549403992 hasRelatedWork W2080325095 @default.
• W2549403992 hasRelatedWork W2135486346 @default.
• W2549403992 hasRelatedWork W2150358226 @default.
• W2549403992 hasRelatedWork W2396648761 @default.
• W2549403992 hasRelatedWork W2442142559 @default.
• W2549403992 hasRelatedWork W2541371606 @default.
• W2549403992 hasRelatedWork W2549403992 @default.
• W2549403992 hasRelatedWork W3101861760 @default.
• W2549403992 isParatext "false" @default.
• W2549403992 isRetracted "false" @default.
• W2549403992 magId "2549403992" @default.
• W2549403992 workType "article" @default.